Costs and Complications of Respiratory Syncytial Virus and Acute Respiratory Infections in the Adult Population: Analysis of a German Claims Database
Authors:
Open Access
- 19 March 2025
- journal article
- research article
- Published by Springer Nature in PharmacoEconomics - Open
- Vol. 9 (3) , 445-459
Abstract
Background Respiratory syncytial virus (RSV) infections pose health and economic burdens to adults. Using claims data, we estimated RSV-associated costs, healthcare resource utilization (HCRU), and complication rates from patients of a nationwide German health insurance database. Methods We analyzed confirmed RSV, RSV-possible, and acute respiratory infection (ARI) cohorts, plus 1:1 matched control cohorts of individuals ≥ 18 years from 2010 to 2019. Matching was performed separately for patients 18–49, 50–59, and ≥ 60 years. Medical costs, HCRU, and sick leave were assessed for inpatients and outpatients. Complications were compared between cases and controls, and logistic regression assessed odds ratios (ORs) for risk. Results Altogether, 2668 confirmed RSV index episodes occurred. In ≥ 60-year-olds, 862 episodes incurred mean excess costs of €3773 (95% confidence interval [CI]: €2956–€4591) per episode during the index quarter and €3286 (95% CI: €1841–€4732) in the following four quarters. Mean costs were €5553 per episode for inpatients and €116 for outpatients. In ≥ 60-year-olds, risk for congestive heart failure hospitalization (OR 2.3; 95% CI: 1.4–3.8), exacerbation of asthma (OR 6.0; 95% CI: 1.7–20.9), and chronic obstructive pulmonary disease (OR 3.9; 95% CI: 2.6–5.8) were higher for confirmed RSV than controls. In younger groups, costs, HCRU, and complications were also higher in cases than controls. The complication frequencies increased with age. RSV-possible episodes incurred mean excess costs of €615 (95% CI: €605–€626) during the index quarter and €610 (95% CI: €583–€637) during the following four quarters, while in the ARI cohort, the excess costs were €1003 (95% CI: €991–€1015) during the index quarter and €1003 (95% CI: €973–€1032) in the following four quarters. For all three cohorts, individuals who had comorbidities, were immunocompromised, or living in long-term care facilities incurred higher costs. Conclusions Confirmed RSV is associated with high excess costs – especially in hospital settings – and HCRU. Complication risk increased with RSV presence. Graphical AbstractKeywords
Funding Information
- GSK
This publication has 34 references indexed in Scilit:
- The Burden of Respiratory Syncytial Virus (RSV) in Germany: A Comprehensive Data Analysis Suggests Underdetection of Hospitalisations and Deaths in Adults 60 Years and OlderInfectious Diseases and Therapy, 2024
- Estimated Incidence of Hospitalizations and Deaths Attributable to Respiratory Syncytial Virus Infections Among Adults in Germany Between 2015 and 2019Infectious Diseases and Therapy, 2024
- RSV vaccination strategies for high-risk patients 2023: a collaborative position paper by leading German medical societies and organizationsInfection, 2023
- Hospitalizations due to respiratory syncytial virus (RSV) infections in Germany: a nationwide clinical and direct cost data analysis (2010–2019)Infection, 2023
- Focusing on severe infections with the respiratory syncytial virus (RSV) in adults: Risk factors, symptomatology and clinical course compared to influenza A / B and the original SARS-CoV-2 strainJournal of Clinical Virology, 2023
- Evaluating the Individual Healthcare Costs and Burden of Disease Associated with RSV Across Age GroupsPharmacoEconomics, 2022
- Evaluation einer ICD-10-basierten elektronischen Surveillance akuter respiratorischer Erkrankungen (SEEDARE) in DeutschlandBundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, 2016
- Respiratory Syncytial Virus Infection in Older Adults: An Under-Recognized ProblemDrugs & Aging, 2015
- Gute Praxis Sekundärdatenanalyse (GPS): Leitlinien und EmpfehlungenDas Gesundheitswesen, 2015
- Impact of Respiratory Virus Infections on Persons With Chronic Underlying ConditionsJAMA, 2000